Search - tctmd.com

Displaying 121 - 140 of 547

Sort: Relevancy | Date

Most Takotsubo Patients Die From CV Causes, but Standard Meds No Help

News Daily News

Most Takotsubo Patients Die From CV Causes, but Standard Meds No Help

January 11, 2024

No Signs of Hypoglycemia Causing CVD in CAROLINA and CARMELINA

News Daily News

No Signs of Hypoglycemia Causing CVD in CAROLINA and CARMELINA

Michael O'Riordan

January 05, 2024

DAPT Works When Started Up to 3 Days After Mild Stroke, TIA

News Daily News

DAPT Works When Started Up to 3 Days After Mild Stroke, TIA

January 04, 2024

Top General Cardiology and CVD Prevention News of 2023

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

News Daily News

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

Yael L. Maxwell

December 13, 2023

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

Long-term ALLHAT Data Affirm Parity of Antihypertensive Meds

News Daily News

Long-term ALLHAT Data Affirm Parity of Antihypertensive Meds

December 06, 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

News Daily News

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

December 05, 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

September 19, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.